medigraphic.com

2018, Number 4

<< Back Next >>

Rev Med MD 2018; 9.10 (4)

Incidence and prevalence of Diabetes mellitus type 2 in people receiving care for HIV in a third level health care center in Mexico City

Cano-Torres JO, Caro-Vega YN, Crabtree-Ramírez B, Sierra-Madero JG, Belaunzarán-Zamudio, PF

Language: English
References: 30
Page: 305-310
PDF size: 587.21 Kb.


ABSTRACT

Introduction. The diabetes mellitus type 2 (T2D) burden is rising worldwide, and in Mexico it has been the leading cause of death since 2000. Improved life expectancy of people living with HIV (PLWH) have led to an increase in chronic diseases such as T2D in such population. Estimates of T2D prevalence among HIV-infected adults are lacking, thus we assessed the annual incidence and prevalence of T2D among PLWH in Mexico.
Material and Methods. A retrospective analysis using cohort data of adults receiving care for HIV at the INCMNSZ between 2000-2017 by performing a series of annually repeated cross-sectional analysis to estimate the annual prevalence and incidence of T2D among all people actively receiving care each year, during the study period.
Results. During the period of the study, 3,338 patients were included and 123 were identified as diabetic at the end of follow-up. The annual prevalence of T2D among people receiving care for HIV increased from 2.4% in 2000 to 4.5% in 2017; the median age of T2D diagnosis was 42.15 years after a median of 7.45 years of HIV diagnosis. Also, overall comorbidities were more common in T2D patients (4 vs 1, p‹0.001) when compared to non-T2D from which non-AIDS defining events were more frequent among people with diabetes (3 vs 1, p‹0.001).
Discussion. Our findings revealed that among a population of adults receiving care for HIV at the INCMNSZ, T2D was a relatively infrequent comorbidity but with a high burden of comorbidities.


REFERENCES

  1. Shamah-Levi T, Cuevas L, Dommarco J HM. Encuesta Nacional de Salud y Nutrición de Medio Camino 2016. (ENSANUT MC 2016). Inst Nac Salud Pública. 2016. doi:10.21149/8593. 2.Bello-Chavolla OY, Rojas-Martinez R, Aguilar- Salinas CA, Hernández-Avila M. Epidemiology of diabetes mellitus in Mexico. Nutr Rev. 2017;75:4-12. doi:10.1093/nutrit/nuw030.

  2. Secretaria de Salud. Estadisticas de Mortalidad en Mexico: muertes registradas en el año 2000. Vol. 44. Salud Publica de Mexico; 2002:266–282.

  3. El-Sappagh S, Kwak D, Ali F, Kwak KS. DMTO: A realistic ontology for standard diabetes mellitus treatment. J Biomed Semantics. 2018;9(1):1-30. doi:10.1186/s13326-018-0176-y.

  4. American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018. Diabetes Care. Supplem 41(13-27).

  5. International Diabetes Federation. IDF Atlas. Available from: http://www.idf.org/diabetesatlas. Accessed 31 May 2018.

  6. K. Zarkogianni et al., “A Review of Emerging Technologies for the Management of Diabetes Mellitus,” in IEEE Transactions on Biomedical Engineering, vol. 62, no. 12, pp. 2735-2749, Dec. 2015.

  7. Mozayani A, Raymon L: Handbook of drug interactions a clinical and forensic guide, springer science+business media LLC, New York, second edition, 2012.

  8. Chen RC, Huang YH, Bau CT, Chen CM. A recommendation system based on domain ontology and SWRL for anti-diabetic drugs selection. Expert Syst Appl. 2012;39:3995–4006.

  9. Smith C, Sabin C a, Lundgren JD, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS. 2010;24(10):1537-1548. doi:10.1097/QAD.0b013e32833a0918.

  10. Nakagawa F, Lodwick RK, Smith CJ, et al. Projected life expectancy of people with HIV according totimingof diagnosis. AIDS. 2012;26(3):335-343. doi:10.1097/QAD.0b013e32834dcec9.

  11. Buchacz K, Baker RK, Palella FJ, et al. Disparities in prevalence of key chronic diseases by gender and race/ethnicity among antiretroviraltreated HIVinfected adults in the US. Antivir Ther. 2013;18(1):65- 75. doi:10.3851/IMP2450.

  12. Avila-Funes JA, Belaunzarán-Zamudio PF, Tamez- Rivera O, Crabtree-Ramírez B, Navarrete-Reyes AP, Cuellar-Rodríguez JM, Sierra-Madero J, Amieva H. Correlates of Prevalent Disability among HIVInfected Elderly Patients. AIDS Res Hum Retroviruses. 2016 Feb; 3.

  13. Wu M, Fatukasi O. et al. for the Neuropsychology Working Group of the Multicenter AIDS Cohort Study. HIV disease and diabetes interact to affect brain white matter hyperintensities and cognition. AIDS. 2018;May 22([Epub ahead of print]). doi:10.1097/QAD.0000000000001891.

  14. Park J, Zuñiga J. Chronic Kidney Disease in Persons Living with HIV: A Systematic Review. J Assoc Nurses AIDS Care. 2018;April 19(S1055- 3290(18)30081-5.):[Epub ahead of print].

  15. Oni T, Berkowitz N, Kubjane M, Goliath R, Levitt NS, Wilkinson RJ. Trilateral overlap of tuberculosis, diabetes and HIV-1 in a high-burden African setting: Implications for TB control. Eur Respir J. 2017;50(1). doi:10.1183/13993003.00004-2017.

  16. Smit M, Cassidy R, Cozzi-Lepri A, et al. Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A.: A modelling study. PLoS One. 2017;12(10):1-12. doi:10.1371/journal.pone.0186638.

  17. Arredondo A, de Icaza E. Financial requirements for the treatment of diabetes in Latin America: implications for the health system and for patients in Mexico. Diabetologia. 2009;52:1693–1695.

  18. Belaunzarán-Zamudio PF, Caro-Vega YN, Shepherd BE, et al. Monitoring of HIV treatment in seven countries in the WHO Region of the Americas. Bull World Health Organ. 2015;93(8):529- 539. doi:10.2471/BLT.14.147447.

  19. Duda SN, Shepherd BE, Gadd CS, Masys DR, McGowa n C C. Measuring the quality of observational study data in an international HIV research network. PLoS One. 2012;7(4):3-8. doi:10.1371/journal.pone.0033908.

  20. World Medical Association. World Medical Association Declaration of Helsinki. JAMA. 2013;310(20):2191. doi:10.1001/jama.2013.281053.

  21. Brown TT, Tassiopoulos K, Bosch RJ, et al. Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes Care 2010;33:2244–9.

  22. Ghislain M, Bastard JP, Meyer L, et al. Late antiretroviral therapy (ART) initiation is associated withlong-termpersistence of systemic inflammation and metabolic abnormalities. PLoS ONE 2015;10:e0144317.

  23. Paik IJ, Kotler DP. The prevalence and pathogenesis of diabetes mellitus in treated HIV-infection. Best Pract Res Clin Endocrinol Metab 2011;25:469–78.

  24. Caro-Vega Y, Belaunzarán-Zamudio P, Crabtree- Ramírez B. Trends in proportion of older HIVinfected people in care in Latin America and the Caribbean: a growing challenge. Epidemiol Infect. 2018;30:1-4.

  25. Zamudio-Rodríguez A, Belaunzarán-Zamudio P, Sierra-Madero J. Association Between Frailty and HIV-Associated Neurodegenerative Disorders Among Older Adults Living with HIV. AIDS Res Hum Retroviruses. 2018;34(5):449-455.

  26. Belaunzarán-Zamudio P, Caro-Vega Y, Crabtree- Ramírez B. Increased age-adjusted mortality and incidence of non-AIDS defining events among people living with HIV enrolled after 50yo and aging in care in Latin America. A CCASAnet cohort study (Abstract O133). HIV Hepat Am 2017.

  27. Haffner SM, Mykkanen L, Festa A, Burke JP, and Stern MP. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: Implications for preventing coronary heart disease during the prediabetic state. Circulation. 2000;101(9):975-980.

  28. Oeseburg H, de Boer RA, van Gilst WH, et al. Telomere biology in healthy aging and disease. Pflugers Arch 2010;459:259–68.

  29. United States Preventive Services Task Force Screening for Type II Diabetes Mellitus in Adults. 2008. Available at http://www.uspreventiveservicestaskforce.org/Pag e/Document/UpdateSummaryFinal/diabetesmellitus- type-2-in-adults-screening.

  30. Abnormal Blood Glucose and Type 2 Diabetes Mellitus: Screening. United States Preventive Services Task Force; 2015. Final Recommendation Statement. Available at http://www.uspreventiveservicestaskforce.org/page/Document/Recommendation-StatementFinal/scree.




2020     |     www.medigraphic.com